Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The endocrine effects of bitter tastant administration in the gastrointestinal system: intragastric versus intraduodenal administration

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reply to Rodgers: The hepatic glucose-mobilizing effect of glucagon is not mediated by cyclic AMP most of the time

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. The glucose-mobilizing effect of glucagon at fasting is mediated by cyclic AMP

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cholecystokinin and panic disorder: reflections on the history and some unsolved questions

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Acute ketosis inhibits appetite and decreases plasma concentrations of acyl ghrelin in healthy young men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Expression of cholecystokinin and its receptors in the intestinal tract of type 2 diabetes patients and healthy controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Gastrin and the moderate hypergastrinemias

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Wout Verbeure
  • Eveline Deloose
  • Joran Tóth
  • Jens F Rehfeld
  • Lukas Van Oudenhove
  • Inge Depoortere
  • Jan Tack
Vis graf over relationer

Bitter tastants are recently introduced as potential hunger-suppressive compounds, the so-called "Bitter pill." However, the literature about bitter administration lacks consistency in methods and findings. We want to test whether hunger ratings and hormone plasma levels are affected by: 1) the site of administration: intragastrically (IG) or intraduodenally (ID), 2) the bitter tastant itself, quinine hydrochloride (QHCl) or denatonium benzoate (DB), and 3) the timing of infusion. Therefore, 14 healthy, female volunteers participated in a randomized, placebo-controlled six-visit crossover study. After an overnight fast, DB (1 µmol/kg), QHCl (10 µmol/kg), or placebo were given IG or ID via a nasogastric feeding tube. Blood samples were taken 10 min before administration and every 10 min after administration for a period of 2 h. Hunger was rated at the same time points on a visual analogue scale. ID bitter administration did not affect hunger sensations, motilin, or acyl-ghrelin release compared with its placebo infusion. IG QHCl infusion tended to suppress hunger increase, especially between 50 and 70 min after infusion, simultaneously with reduced motilin values. Here, acyl-ghrelin was not affected. IG DB did not affect hunger or motilin, however acyl-ghrelin levels were reduced 50-70 minutes after infusion. Plasma values of glucagon-like peptide 1 and cholecystokinin were too low to be properly detected or to have any physiological relevance. In conclusion, bitter tastants should be infused into the stomach to reduce hunger sensations and orexigenic gut peptides. QHCl has the best potential to reduce hunger sensations, and it should be infused 60 min before food intake.NEW & NOTEWORTHY Bitter tastants are a potential new weight-loss treatment. This is a noninvasive, easy approach, which should be received with considerable enthusiasm by the public. However, literature about bitter administration lacks consistency in methods and findings. We summarize how the compound should be given based on: the site of administration, the best bitter compound to use, and at what timing in respect to the meal. This paper is therefore a fundamental step to continue research toward the further development of the "bitter pill."

OriginalsprogEngelsk
TidsskriftAmerican Journal of Physiology: Endocrinology and Metabolism
Vol/bind321
Udgave nummer1
Sider (fra-til)E1-E10
ISSN0193-1849
DOI
StatusUdgivet - 1 jul. 2021

ID: 66793026